Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →More from Derisofer
Other strengths and forms by Ziska Pharmaceuticals Ltd.
Indications & Uses
Derisofer is indicated for:
Pharmacology
Ferric derisomaltose is an iron replacement product given by intravenous infusion. The ferric derisomaltose in it is an iron carbohydrate complex with a matrix structure, built from interchanging layers of ferric hydroxide and a carbohydrate called derisomaltose.
Derisomaltose is made of linear, hydrogenated isomaltooligosaccharides. Their average molecular weight is 1000 Da, and the molecular weight distribution is narrow, with almost no mono- and disaccharides present. So ferric derisomaltose is a complex of iron (III) hydroxide and derisomaltose, an iron carbohydrate oligosaccharide that releases iron. The released iron binds to transferrin, which carries it to erythroid precursor cells, where it is incorporated into hemoglobin.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
For patients who weigh 50 kg or more, Ferric Derisomaltose is given as 1,000 mg by intravenous infusion over at least 20 minutes, as a single dose. If iron deficiency anemia comes back, the dose can be repeated.
For patients who weigh less than 50 kg, the dose is 20 mg/kg of actual body weight, again by intravenous infusion over at least 20 minutes as a single dose. If iron deficiency anemia comes back, the dose can be repeated.
The dose of Ferric Derisomaltose is expressed in mg of elemental iron. Each mL contains 100 mg of elemental iron. Give Ferric Derisomaltose only where staff and treatments are immediately available to manage serious hypersensitivity reactions.
Side Effects
With Ferric Derisomaltose, the side effects reported most often (in at least 1% of people) are rash and nausea.
Cautions & Contraindications
Warnings & Precautions
Serious hypersensitivity reactions, including anaphylactic-type reactions, have been reported in patients receiving Ferric Derisomaltose. Some of these were life-threatening and some were fatal. Patients may present with shock, clinically significant hypotension, loss of consciousness and/or collapse. Watch patients for signs and symptoms of hypersensitivity during the infusion and after it, for at least 30 minutes and until they are clinically stable once the infusion is complete. Give Ferric Derisomaltose only where staff and treatments for serious hypersensitivity reactions are immediately available. It must not be used in patients who have had a serious hypersensitivity reaction to Ferric Derisomaltose or any of its components. In clinical trials in patients with IDA and CKD, serious or severe hypersensitivity was reported in 0.3% (6/2008) of the patients treated with Ferric Derisomaltose. These included 3 events of hypersensitivity in 3 patients, 2 events of infusion-related reactions in 2 patients and 1 event of asthma in one patient. Iron Overload: Too much parenteral iron therapy can lead to excess iron storage and possibly iatrogenic hemosiderosis or hemochromatosis. Monitor the haematologic response (hemoglobin and hematocrit) and the iron parameters (serum ferritin and transferrin saturation) during parenteral iron therapy. Do not give Ferric Derisomaltose to patients with iron overload.
Contraindications
Ferric Derisomaltose must not be given to anyone who has had a serious hypersensitivity reaction to Ferric Derisomaltose or to any of its components. In past reactions, patients have gone into shock, had a clinically significant drop in blood pressure, lost consciousness, or collapsed.
Pregnancy & Breastfeeding
There are no data on the use of Ferric Derisomaltose in pregnant women that could show whether it carries a risk of major birth defects, miscarriage, or harmful outcomes for the mother or the baby. Published studies of intravenous iron products in pregnant women have not reported any link with adverse developmental outcomes. But these studies can't confirm or rule out a drug-related risk during pregnancy, because they were not designed to look at the risk of major birth defects.
For breastfeeding, the data on Ferric Derisomaltose in lactating women show that iron is present in breast milk. The data don't tell us how much iron the breastfed child may be exposed to, or what effect the medicine has on milk production. The mother's clinical need for Ferric Derisomaltose should be weighed against the developmental and health benefits of breastfeeding. Any possible adverse effects on the breastfed child, whether from the medicine or from the mother's underlying condition, should also be considered.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Use in Special Populations
Ferric Derisomaltose has not been shown to be safe or effective in children, so its use in pediatric patients is not established.
Overdose
Too much Ferric Derisomaltose can cause iron to build up in the body's storage sites, and this may lead to hemosiderosis and hemochromatosis. So don't use Ferric Derisomaltose in patients who already have iron overload.
⚠️ In an emergency call 999 or go to the nearest hospital emergency department.
Storage
Keep Ferric Derisomaltose at 20° to 25°C. Short periods between 15° and 30°C are permitted. Don't let it freeze.
Common questions about Derisofer 500 mg/5 ml
What is Derisofer 500 mg/5 ml IV Injection?
Derisofer 500 mg/5 ml IV Injection is a medicine that contains Ferric Derisomaltose. It is made by Ziska Pharmaceuticals Ltd. It belongs to the Parenteral Iron Preparations group of medicines.
What is Derisofer used for?
Derisofer is used for: Anemia.
What are the side effects of Derisofer?
With Ferric Derisomaltose, the side effects reported most often (in at least 1% of people) are rash and nausea.
Can I take Derisofer during pregnancy or while breastfeeding?
There are no data on the use of Ferric Derisomaltose in pregnant women that could show whether it carries a risk of major birth defects, miscarriage, or harmful outcomes for the mother or the baby. Published studies of intravenous iron products in pregnant women have not reported any link with adverse developmental outcomes. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
What happens if I take too much Derisofer?
Too much Ferric Derisomaltose can cause iron to build up in the body's storage sites, and this may lead to hemosiderosis and hemochromatosis. So don't use Ferric Derisomaltose in patients who already have iron overload. In an emergency call 999 or go to the nearest hospital emergency department.
How should I store Derisofer?
Keep Ferric Derisomaltose at 20° to 25°C. Short periods between 15° and 30°C are permitted.
Do I need a prescription for Derisofer?
Derisofer is a prescription (Rx) medicine. Take it as your doctor advises.